ReviewPharmacy (Basel, Switzerland)2020
Factors Impacting Pharmaceutical Prices and Affordability: Narrative Review.
Review in Pharmacy (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Observational
- Pricing of innovative medicines and advanced therapies worldwide: an scoping review.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Assessment of Blockchain Technology in the Improvement of Supply Chain Management in the Pharmaceutical Industry.Recent patents on biotechnology · 2026Review
- A Data-Driven Approach for Estimating Type 2 Diabetes-Related Costs in Greece.Journal of market access & health policy · 2025Article
- Patterns of Prescription Switching in a Uniform-Pricing System for Multi-Source Drugs: A Retrospective Population-Based Cohort Study.Healthcare (Basel, Switzerland) · 2025Article
- Cost effectiveness of mono, dual, and triple therapy of antihypertensive drugs: a retrospective cohort study.Cost effectiveness and resource allocation : C/E · 2025Article
- Cost comparison of phosphodiesterase type 5 inhibitors: rural vs urban New York State counties and online pharmacies.Sexual medicine · 2025Article
- Designing pathways for bioproducing complex chemicals by combining tools for pathway extraction and ranking.Nature communications · 2025Article
- What Does Pharmaceutical 3D Printing Cost? A Framework and Case Study with Hydrocortisone for Adrenal Insufficiency.PharmacoEconomics - open · 2025Article
- Pharmacoeconomic perspectives on HIV: integrating data for long-term treatment and prevention.Frontiers in medicine · 2025Review
- Regulation of mark-up on medicine prices in Zimbabwe: a pilot survey from 92 community pharmacies in the metropolitan area of Harare.Health economics review · 2024Article
- Deciphering Factors Contributing to Cost-Effective Medicine Using Machine Learning.Bioengineering (Basel, Switzerland) · 2024Article
- Conceptualisation and Role of Market Access in Pharmaceutical Industry: A Scoping Review.Journal of market access & health policy · 2024Article
- Private sector availability and affordability of under 5 malaria health commodities in selected states in Nigeria and the Federal Capital Territory.Journal of pharmaceutical policy and practice · 2024Article
- Cancer medicines: a private vice for public benefit?Ecancermedicalscience · 2024Article
- India's Decision to Deny an Extension of Patent for Bedaquiline: A Public Health Imperative.Cureus · 2023Review
- Impact of China's National Volume-Based Procurement on Drug Procurement Price, Volume, and Expenditure: An Interrupted Time Series Analysis in Tianjin.International journal of health policy and management · 2023Article
- A quasi-experimental study of the volume-based procurement (VBP) effect on antiviral medications of hepatitis B virus in China.Frontiers in pharmacology · 2023Article
- Critical Success Factors and Traceability Technologies for Establishing a Safe Pharmaceutical Supply Chain.Methods and protocols · 2021Review
- Overview on development of ASEAN traditional and herbal medicines.Chinese herbal medicines · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increasing prescription drug pricing often reflects additional work stress on medical professionals because they function as financial advisors for patients and help them manage out-of-pocket expenses. Providers or prescribers wish to help patients with prescription costs but often lack related information. Healthcare plan providers try to display prescription and drug cost information on their websites, but such data may not be linked to electronic prescription software. A mark-up is defined as the additional charges and costs that are applied to the price of a product for the purpose of covering overhead costs, distribution charges, and profit. Therefore, the policies implemented in the pharmaceutical distribution chain might include the regulation of wholesale and retails mark-ups and pharmaceutical remuneration. If mark-ups are regulated, countries are highly recommended to use regressive mark-ups rather than fixed percentage mark-ups. This narrative review provides insights into the framework of pharmaceutical mark-up systems by describing different factors impacting pharmaceutical prices and affordability. These include the interplay of medicine pricing and the supply chain, the impact of pertinent laws and regulation and out-of-pocket expenditure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.